Warfarin/Yeni Nesil Oral Antikoagülan ve K-Vitamini Zehirlenmeleri
Özet
Warfarin gibi K vitamini antagonistleri (VKA), tromboembolizm önlemede oldukça etkili olsalar da sık izlem, doz ayarlaması ve gıda-ilaç etkileşimleri nedeniyle kullanımı sınırlıdır. Bu sınırlamaları aşmak amacıyla geliştirilen Yeni Nesil Oral Antikoagülanlar (YOAC); Apixaban, Dabigatran, Edoksaban ve Rivaroksaban rutin izleme veya doz ayarlaması gerektirmeden pıhtılaşma kademesindeki spesifik faktörleri (faktör Xa veya trombin) hedefler. Warfarin, K vitaminini inhibe ederek pıhtılaşma faktörlerinin sentezini engeller; etkisi 12 saatte başlayıp 72 saatte pik seviyeye ulaşır ve antidotu K vitamini ile Protrombin Kompleksi Konsantresi’dir (PCC). YOAC’lardan Dabigatran geri dönüşümlü bir trombin inhibitörüdür, hemodiyaliz ile vücuttan uzaklaştırılabilen tek YOAC olma özelliğine sahiptir ve spesifik antidotu İdarucizumab’tır. Selektif faktör Xa inhibitörleri olan Apixaban, Rivaroksaban ve Edoksaban vakalarında diyaliz etkisizdir; bu ilaçların antidotu olarak rekombinant bir faktör Xa proteini olan Andexanet alfa kullanılırken, Ciraparantag ise değerlendirme aşamasındadır. Pıhtılaşma proteinlerinin karboksilasyonu için kofaktör görevi gören K vitamininin eksikliği kanama problemlerine yol açarken, toksisitesi oldukça nadirdir ve çoğunlukla insanlarda kullanımı olmayan menadion formu ile ilişkilidir. Menadion toksisitesi, karaciğerde oksijen alımını ve lipid peroksidasyonunu artırarak hepatosit hasarına, sarılık, hiperbilirubinemi ve hemolitik anemi belirtilerine yol açmaktadır.
Although vitamin K antagonists (VKAs) such as warfarin are highly effective in preventing thromboembolism, their use is restricted due to frequent monitoring, dose adjustments, and food-drug interactions. Novel Oral Anticoagulants (NOACs)—apixaban, dabigatran, edoxaban, and rivaroxaban—were developed to overcome these limitations, targeting specific factors in the coagulation cascade (factor Xa or thrombin) without requiring routine monitoring or dose adjustments. Warfarin inhibits vitamin K, preventing the synthesis of clotting factors; its effect begins in 12 hours, peaks at 72 hours, and its antidote is vitamin K combined with Prothrombin Complex Concentrate (PCC). Among NOACs, dabigatran is a reversible thrombin inhibitor, the only NOAC removable via hemodialysis, and its specific antidote is idarucizumab. Dialysis is ineffective for selective factor Xa inhibitors (apixaban, rivaroxaban, and edoxaban), where andexanet alfa—a recombinant factor Xa protein—serves as the antidote, while ciraparantag remains under evaluation. While vitamin K deficiency, essential as a cofactor for the carboxylation of clotting proteins, causes bleeding issues, its toxicity is extremely rare and mainly associated with menadione, which has no human use. Menadione toxicity increases oxygen uptake and lipid peroxidation in the liver, leading to hepatocyte damage, jaundice, hyperbilirubinemia, and hemolytic anemia.
Referanslar
Zapata LV, Hansten PD, Panic J, et al. Risk of Bleeding with Exposure to Warfarin and Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review and Meta-Analysis. Thrombosis and haemostasis. 2020; 120 (7): 1066.
Hu TY, Vaidya VR, and Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vascular health and risk management. 2016; 12: 35–44.
Vu TT, and Gooderham M. Adverse drug reactions and cutaneous manifestations associated with anticoagulation. Journal of Cutaneous Medicine and Surgery. 2017; 1(6):540-550.
Baker RI, Coughlin PB, Gallus AS et al. The Warfarin Reversal Consensus Group Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Medical Journal of Australia. 2004; 181(9):494-497.
Kumar R, Smith RE, and Henry BL. A review of and recommendations for the management of patients with life-threatening dabigatran-associated hemorrhage: a single-center university hospital experience. Journal of intensive care medicine. 2015; 30(8): 462-472.
Chiew AL, Khamoudes D, and Chan BSH. Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. Clinical toxicology. 2014; 52(4):283-287.
Wood P. New oral anticoagulants: an emergency department overview. Emergency Medicine Australasia.2013; 25(6):503-514.
Siegal DM, Curnutte JT, Conolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. New England Journal of Medicine. 2015; 373(25):2413-2424.
Rasmussen, SE,Andersen NL, Dragsted LO, et al. A safe strategy for addition of vitamins and minerals to foods. European Journal of Nutrition. 2006; 45(3):123-135.